Searching for a Novel HLA-Cw6-Linked Cardiometabolic Endotype in Psoriatic Disease.

HLA-Cw6 cardiometabolic comorbidity diabetes psoriasis psoriatic arthritis psoriatic disease

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
25 Sep 2024
Historique:
received: 30 08 2024
revised: 20 09 2024
accepted: 23 09 2024
medline: 26 10 2024
pubmed: 26 10 2024
entrez: 26 10 2024
Statut: epublish

Résumé

In recent years, a possible connection between HLA-Cw6 and a distinctive cardiometabolic (CM) profile in patients with psoriatic disease (PsD) has been proposed, although there is still little support for this. Our aim was to further investigate this possible association by studying a large population of PsD patients. For this study, three different cohorts of patients with PsD were analyzed: two with a majority of cutaneous psoriasis, pooled n: 600, and a third with only psoriatic arthritis-PsA-cases, n: 340. Potential relationships between HLA-Cw6 and the different CM risk factors (hypertension, diabetes, obesity, dyslipidemia) were analyzed using univariate and multivariate regression models, while the final net effect was assessed using fixed- or random-effects meta-analyses, as appropriate. In the PsA cohort, no association was detected between HLA-Cw6 carriership and any of the CM comorbidity factors. In psoriasis cohorts, after correcting for age, sex, disease duration, and arthritis, HLA-Cw6 carriers had a reduced diabetes risk (OR 0.49, 95%CI: 0.26-0.91, This work demonstrates a potential protective effect of the HLA-Cw6 allele on the risk of diabetes in PsD. Our findings together with those of others seem to confirm the existence of a novel HLA-Cw6-linked cardiometabolic endotype in this disease.

Sections du résumé

BACKGROUND/OBJECTIVES OBJECTIVE
In recent years, a possible connection between HLA-Cw6 and a distinctive cardiometabolic (CM) profile in patients with psoriatic disease (PsD) has been proposed, although there is still little support for this. Our aim was to further investigate this possible association by studying a large population of PsD patients.
METHODS METHODS
For this study, three different cohorts of patients with PsD were analyzed: two with a majority of cutaneous psoriasis, pooled n: 600, and a third with only psoriatic arthritis-PsA-cases, n: 340. Potential relationships between HLA-Cw6 and the different CM risk factors (hypertension, diabetes, obesity, dyslipidemia) were analyzed using univariate and multivariate regression models, while the final net effect was assessed using fixed- or random-effects meta-analyses, as appropriate.
RESULTS RESULTS
In the PsA cohort, no association was detected between HLA-Cw6 carriership and any of the CM comorbidity factors. In psoriasis cohorts, after correcting for age, sex, disease duration, and arthritis, HLA-Cw6 carriers had a reduced diabetes risk (OR 0.49, 95%CI: 0.26-0.91,
CONCLUSIONS CONCLUSIONS
This work demonstrates a potential protective effect of the HLA-Cw6 allele on the risk of diabetes in PsD. Our findings together with those of others seem to confirm the existence of a novel HLA-Cw6-linked cardiometabolic endotype in this disease.

Identifiants

pubmed: 39457487
pii: biomedicines12102174
doi: 10.3390/biomedicines12102174
pii:
doi:

Types de publication

Journal Article

Langues

eng

Auteurs

Rubén Queiro (R)

Rheumatology Division, Central University Hospital of Asturias, 33011 Oviedo, Spain.
Department of Medicine, Oviedo University School of Medicine, 33006 Oviedo, Spain.
Translational Immunology Division, Biohealth Research Institute of the Principality of Asturias (ISPA), 33011 Oviedo, Spain.
Rheumatology & ISPA Translational Immunology Division, Hospital Universitario Central de Asturias, Avenida de Roma, S/N 33011, 33011 Oviedo, Spain.

Pablo González Del Pozo (P)

Rheumatology Division, Central University Hospital of Asturias, 33011 Oviedo, Spain.

Paula Alvarez (P)

Rheumatology Division, Central University Hospital of Asturias, 33011 Oviedo, Spain.

Norma Calleja (N)

Rheumatology Division, Central University Hospital of Asturias, 33011 Oviedo, Spain.

Ignacio Braña (I)

Rheumatology Division, Central University Hospital of Asturias, 33011 Oviedo, Spain.

Marta Loredo (M)

Rheumatology Division, Central University Hospital of Asturias, 33011 Oviedo, Spain.

Estefanía Pardo (E)

Rheumatology Division, Central University Hospital of Asturias, 33011 Oviedo, Spain.

Stefanie Burger (S)

Rheumatology Division, Central University Hospital of Asturias, 33011 Oviedo, Spain.

Sara Alonso (S)

Rheumatology Division, Central University Hospital of Asturias, 33011 Oviedo, Spain.

Mercedes Alperi (M)

Rheumatology Division, Central University Hospital of Asturias, 33011 Oviedo, Spain.

Classifications MeSH